Ascendis Pharma Balance Sheet Health
Financial Health criteria checks 0/6
Ascendis Pharma has a total shareholder equity of €-145.7M and total debt of €545.5M, which brings its debt-to-equity ratio to -374.4%. Its total assets and total liabilities are €825.6M and €971.3M respectively.
Key information
-374.4%
Debt to equity ratio
€545.47m
Debt
| Interest coverage ratio | n/a |
| Cash | €399.44m |
| Equity | -€145.70m |
| Total liabilities | €971.28m |
| Total assets | €825.59m |
Recent financial health updates
Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?
Nov 10
Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?
Jun 27Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?
Feb 18Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?
Sep 24Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money
Jun 10Is Ascendis Pharma (NASDAQ:ASND) In A Good Position To Invest In Growth?
Jan 07Recent updates
Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S
Apr 05Ascendis Pharma's Ambitious Vision 2030
Jan 11What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You
Dec 21Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?
Nov 10Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing
Oct 05Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?
Jun 27Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week
May 05Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?
Feb 18Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?
Sep 24Ascendis Pharma: TransCon CNP Data Coming Q4
Sep 15Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH
Aug 31Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa
Aug 11Ascendis Pharma: Institutional Buying Values Dutch Biotech Best-Now Cap-Gain Prospect
Aug 03Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money
Jun 10Ascendis Pharma: Biotech Bear Provides Attractive Entry Point
May 09Ascendis: Institutional Buying Activity Now Seen As Good Value By Market-Makers
Apr 29Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 51% Above Its Share Price
Feb 24Is Ascendis Pharma (NASDAQ:ASND) In A Good Position To Invest In Growth?
Jan 07Ascendis: Danish Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Dec 30Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 97% Above Its Share Price
Sep 24Ascendis Pharma: A Promising Platform And A Rich Valuation
Sep 10We're Hopeful That Ascendis Pharma (NASDAQ:ASND) Will Use Its Cash Wisely
Aug 12Best Biotech Stock (Now): Ascendis Pharma, Where Best = Capital Gain ODDS Next 3 Months
Jun 30Financial Position Analysis
Short Term Liabilities: ASND has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ASND has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ASND has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ASND's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ASND has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ASND has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.